Abstract
The time of diagnosis is crucial for type 2 diabetes mellitus (T2DM) in terms of disease severity and chronic complications, as initial glycated haemoglobin (HbA1c) predicts 5-year cardiovascular mortality. The Italian health-care system relies on about 650 diabetes care units (DCU) interfacing with a large number of general practitioners (GPs). It may thus reach the goal of preventing complications easier than others by adopting a more comprehensive multifactorial approach. To assess whether the interval between diagnosis and referral to the DCU might influence the course of the disease in terms of HbA1c, associated cardiovascular risk factors, drug utilisation, and chronic complications in the elderly, the electronic records of 313 elderly T2DM patients (74.6 ± 4.9 years) followed by their GPs until referral to our DCU were retrospectively analysed for the above-mentioned parameters and divided into an early referral (ER) group (diagnosed within 12 months, n = 111) and a late referral (LR) group (diagnosed >12 months before, n = 202). A further set of 200 patients routinely taken care by our DCU, matched with the LR group for age, gender, and disease duration, was classified as “long-standing follow-up” (LSF) and compared to the others to rule out any confounding effects of long-standing disease per se on the clinical outcomes investigated in our study. About 35 % of T2DM patients referred to our DCU within 12 months of diagnosis; the rest did so some 5 years after diagnosis. LR patients displayed worse HbA1c levels (10.8 vs. 7.7 %, p < 0.01), used more drugs, and had more than twice as high complication rates as their ER counterparts. Almost all risk factors and complications were lower in the LSF (0.001 < p < 0.05) and ER groups than in the LR group. In both the ER and the LSF groups, we observed a lower burden of diabetes than in the LR group. This rules out the possibility that disease duration might play a major role per se in the burden of the disease in the elderly as opposed to the thoughtful patient care attitude exhibited by the DCU. A better and more efficient organisation has to be developed, including a strong interaction among GPs, diabetes specialists, and elderly people with T2DM allowing the latter to take charge of their own disease management through a sustained empowerment policy.
Similar content being viewed by others
References
Kerr D, Partridge H, Knott J, Thomas PW (2011) HbA1c 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes. Diabet Med 28:1520–1524
Ceriello A, Ihnat MA, Thorpe JE (2009) Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 94:410–415
Ceriello A (2012) The emerging challenge in diabetes: the “metabolic memory”. Vascul Pharmacol 57:133–138
Monnier L, Colette C, Owens D (2012) The glycemic triumvirate and diabetic complications: is the whole greater than the sum of its component parts? Diabetes Res Clin Pract 95:303–311
Nalysnyk L, Hernandez-Medina M, Krishnarajah G (2010) Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 12:288–298
Kilpatrick ES, Rigby AS, Atkin SL (2010) For debate. Glucose variability and diabetes complication risk: we need to know the answer. Diabet Med 27:868–871
Turner RC, Holman RR, Cull CA et al (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
Pedersen O, Gaede P (2003) Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. Metabolism 52:19–23
Appropriatezza clinica, strutturale, tecnologica e operative per la prevenzione, diagnosi e terapia dell’obesità e del diabete mellito. Quaderni del Ministero della salute n.10. Poligrafico dello Stato, Roma 2011. Last access on 4 Oct 2013: http://www.quadernidellasalute.it/archivio-quaderni/10-luglio-agosto-2011.php
Giorda C, Petrelli A, Gnavi R et al (2006) impact of second-level specialized care on hospitalization in persons with diabetes: a multilevel population-based study. Diabet Med 23:377–383
Watanabe RM (2011) Drugs, diabetes and pharmacogenomics: the road to personalized therapy. Pharmacogenomics 12:699–701
Giorda C, Picariello R, Nada E et al (2012) The impact of adherence to screening guidelines and of diabetes clinics referral on morbidity and mortality in diabetes. PLoS One 7:e33839. doi:10.1371/journal.pone.0033839
Tur J, Alòs M, Iglesias L et al (2011) TRAMOMTANA (Multidisciplinary treatment of morbid obesity: medication, behavioral therapy, nutritional support, and physical activity). From question to reality in an investigator-initiated clinical trial (II). Endocrinol Nutr 58:299–307
Aggarwal C, Langer CJ (2012) Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancer. Curr Opin Oncol 24:130–136
Bauman AE, Reis RS, Sallis JF et al (2012) Correlates of physical activity: why are some people physically active and others not? Lancet 380:258–271
Mathus-Vliegen EM (2012) Obesity management task force of the European association for the study of obesity. Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. Obes Facts 5:460–483
Nouwens E, van Lieshout J, Wensing M (2012) Comorbidity complicates cardiovascular treatment: is diabetes the exception? Neth J Med 70:298–305
Bruno G, De Micheli A, Frontoni S et al (2011) Highlights from “Italian Standards of Care for Diabetes Mellitus 2009–2010”. Nutr Metab Cardiovasc Dis 21:302–314
Schernthaner G (2010) Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 160:8–19
Terry T, Raravikar K, Chokrungvaranon K, Reaven PD (2012) Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes?: insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep 14:79–88
Rana OA, Byrne CD, Greaves K. (2013) Intensive glucose control and hypoglycaemia: a new cardiovascular risk factor? Heart. doi: 10.1136/heartjnl-2013-303871
Hemmingsen B, Lund SS, Gluud C et al (2011) Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343:d6898. doi:10.1136/bmj.d6898
Arcangeli A, Cimino A, Di Bartolo P et al. (2012) Gruppo Annali AMD. Analisi prospettica degli indicatori di qualità dell’assistenza del diabete in Italia (2004–2011). http://www.infodiabetes.it/files/ANNALI-AMD/2012/Annali2012.pdf
Rossi MC, Lucisano G, Comaschi M et al (2011) AMD-QUASAR Study Group. Quality of diabetes care predicts the development of cardiovascular events: results of the AMD-QUASAR Study. Diabetes Care 34:347–352
Gruppo di studio ANNALI AMD (2011) AMD Annals: a model of continuous monitoring and improvement of the quality of diabetes care. Epidemiol Prev 35:18–26
Motta AJ, Koska J, Reaven P, Migrino RQ (2012) Vascular protective effects of diabetes medications that mimic or increase glucagon-like peptide-1 activity. Recent Pat Cardiovasc Drug Discov. 7:2–9
Vilsbøll T, Garber AJ (2012) Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes Obes Metab 14(Suppl 2):41–49
Fonseca VA (2011) Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca. Am J Med. 124(1 Suppl):S54–S61
Kruger DF, Boucher JL, Banerji MA (2011) Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus. Postgrad Med 123:54–62
Gnavi R, Picariello R, la Karaghiosoff L et al (2009) Determinants of quality in diabetes care process: the population-based Torino study. Diabetes Care 32:1986–1992
Ziemer DC, Doyle JP, Barnes CS, Branch CT Jr, Cook CB, El-Kebbi IM, Gallina DL, Kolm P, Rhee MK, Phillips LS (2006) An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting. Improving primary care of African Americans with diabetes (IPCAAD) 8. Arch Intern Med 166:507–513
Shah BR, Hux JE, Laupacis A, Zinman B, Van Walraven C (2005) Clinical inertia in response to inadequate glycemic control. Do specialists differ from primary care physicians? Diabetes Care 28:600–606
van Bruggen R, Gorter K, Stolk R, Klungel O, Rutten G (2009) Clinical inertia in general practice: widespread and related to the outcome of diabetes care. Fam Pract 26:428–436
Bruno G, Picariello R, Petrelli A et al (2012) Direct costs in diabetic and non diabetic people: the population-based Turin study, Italy. Nutr Metab Cardiovasc Dis 22:684–690
Ceriello A, Candido R, De Micheli A, Esposito K, Gallo M, Gentile S, Medea G (for the SIMG). Personalisation of therapy in type 2 diabetes. Last access, 26 May 2013 http://www.aemmedi.it/algoritmi_en_2013/intro-english.html
Conflict of interest
The authors declare no conflicts of interest relevant to this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by Antonio Secchi.
Rights and permissions
About this article
Cite this article
Strollo, F., Guarino, G., Marino, G. et al. Different prevalence of metabolic control and chronic complication rate according to the time of referral to a diabetes care unit in the elderly. Acta Diabetol 51, 447–453 (2014). https://doi.org/10.1007/s00592-013-0537-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-013-0537-z